From 2026 onward, CPHI and PMEC India by Informa Markets in India will transition into two specialised shows—CPHI at Dwarka and PMEC at IEML on consecutive days
New Delhi, December 2025
The sold-out 18th edition of CPHI & PMEC India, organised by Informa Markets in India, successfully concluded at the India Expo Centre, Greater Noida, Delhi-NCR, reaffirming India’s growing influence in the global pharmaceutical ecosystem. The three-day event brought together over 2,000 exhibitors and 50,000+ professionals from more than 120 countries, including China, Italy, Germany, Switzerland, and South Korea, serving as a powerful platform for innovation, collaboration, and strategic business exchange.
Spanning the entire pharmaceutical value chain—ingredients, formulations, machinery, packaging, analytical instruments, laboratory technologies, cleanroom solutions, and advanced manufacturing—the expo enabled meaningful dialogue across traditional and emerging segments of the industry.
Commenting on the success of the edition, Mr. Yogesh Mudras, Managing Director, Informa Markets in India, said:
“India’s pharmaceutical sector has witnessed remarkable growth, with exports reaching USD 30 billion and global life sciences leaders increasingly choosing India as a strategic base. The strong international participation at CPHI & PMEC India reflects global confidence in India’s innovation and manufacturing capabilities. Having reached a natural scale peak with the combined format, the decision to evolve CPHI and PMEC into specialised platforms will enable deeper, more impactful engagement across the value chain.”
Strategic Evolution from 2026
During the event, Informa Markets in India announced that from 2026 onwards, CPHI and PMEC India will transition into two specialised shows across two locations on consecutive days, following extensive stakeholder consultations.
- CPHI India will move to Dwarka, offering a more premium, content-led environment for formulation, ingredients, and finished dosage stakeholders.
- PMEC India will continue at IEML, Greater Noida, optimised for scale and tailored to the machinery and technology ecosystem.
This evolution is designed to provide each platform with sharper focus, deeper engagement, and enhanced business outcomes.
Strong Exhibitor & Association Support
The exhibition featured participation from leading pharmaceutical companies including Dr. Reddy’s Laboratories, Biocon, Jubilant Ingrevia, Akums Drugs & Pharmaceuticals, MSN Laboratories, Gland Pharma, and others, alongside major machinery and technology players such as ACG, Cadmach, Gansons, Shimadzu, Klenzaids, and more.
The event received strong support from industry associations including Pharmexcil, IPEC India, BDMAI, OPPI, FOPE, and the Indian Pharmaceutical Association (IPA), reinforcing its role as a trusted industry platform.
Knowledge Leadership & High-Level Dialogues
CPHI & PMEC India 2025 featured a comprehensive knowledge programme, including the Pharma Connect Congress, which addressed critical themes such as: Innovation-led manufacturing and affordability; Regulatory pathways for EU market access; Digital transformation from R&D to commercialisation; and Emerging opportunities in orphan drug manufacturing, among others.
A highlight of the programme was the Closed-door Pharma Leaders’ Roundtable 2025, themed
“Scripting India Pharma 3.0: Capturing Global Opportunities Amid Shifting Dynamics.”
Senior industry leaders engaged in candid discussions on regulatory priorities, innovation pathways, and global market shifts, reinforcing CPHI India’s role as a platform for policy-shaping dialogue.
The event also hosted the Women in Pharma Roundtable, spotlighting leadership, inclusion, and career progression, and culminated with the India Pharma Awards 2025, celebrating excellence in innovation, sustainability, digital transformation, and lifetime contribution to the sector.
Industry Outlook
India’s pharmaceutical industry continues to evolve rapidly across generics, complex formulations, APIs, biologics, biosimilars, and advanced therapies. With 98 approved biosimilars, growing investments in R&D, digital transformation, quality systems, and regulatory alignment, India is strengthening its position as a global pharma manufacturing and innovation hub. The biosimilars market, currently valued at USD 349 million, is projected to grow to USD 2.1 billion by 2030, underscoring the sector’s long-term potential.
Festivity of Business
CPHI & PMEC India 2025 formed a key part of Informa Markets in India’s Festivity of Business, now in its 6th edition—a 100-day, pan-India campaign encompassing 28 high-impact events, including 16 expos, 5 conferences, and 7 awards shows. Rooted in collaboration and celebration, the campaign reflects India’s economic resilience and its journey toward becoming a $5 trillion economy.
